Orforglipron vs Tirzepatide

Eli Lilly's oral, non-peptide GLP-1 receptor agonist. The first viable once-daily pill competing with injectable semaglutide and tirzepatide. Expected FDA approval in 2026–2027.

A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.

Orforglipron is a small molecule (not a peptide) that mimics GLP-1 binding. Its oral bioavailability is the breakthrough — no injection, no cold-chain storage, no complex dosing schedule.

Tirzepatide activates both GIP and GLP-1 receptors, a combination that appears to amplify glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite beyond what either pathway achieves alone.

12–36 mg oral once daily (in trials)

2.5 mg weekly, titrated up to 15 mg weekly

~25 hours

~5 days

Oral

Subcutaneous once weekly

investigational

approved

Not yet listed

Not yet listed